The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
Rosemary Oil may inhibit the activity of 5α-Reductase, potentially promoting hair growth. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.
The conversation discusses using Minoxidil, finasteride, RU58841, and pyrilutamide for hair loss treatment. The user is considering adding a topical treatment and has not experienced side effects from current treatments.
A user reported hair thickening and a stronger crown after using rosemary shampoo for about a year, with progress pictures as evidence. Some commenters discussed the effectiveness of natural treatments versus pharmaceutical options like Minoxidil and Finasteride.
A potential treatment for alopecia involving a protein that calms hair follicles has shown promise in rats, but skepticism remains about its applicability to humans. Many users express doubt about the timeline for effective hair loss treatments, comparing it to past unfulfilled promises.
A user shared their progress with hair regrowth using a topical solution of 0.3% finasteride and 6% minoxidil spray. They asked for additional routine suggestions, but a reply suggested no changes if the current routine works.
The conversation discusses hair loss treatments, specifically comparing rosemary and Redensyl, with the original poster already using finasteride and minoxidil. Users also mention using topical melatonin, caffeine, geranium, rosemary oil, jojoba, coconut, and argan oil for hair and scalp care.
The conversation is about choosing between RU58841 and topical spironolactone for hair loss treatment. The user is currently using a topical solution with minoxidil, alfatradiol, and progesterone, and is concerned about side effects and effectiveness of both RU58841 and spironolactone.
The conversation discusses Pyrilutamide for hair loss, with skepticism about its legitimacy and mentions of an upcoming press release from Kintor. It also references ongoing trials and includes links for further information.